Franklin Lakes-based BD (Becton, Dickinson and Co.) on June 8 announced it received pandemic orders for needles and syringes totaling 2 billion injection devices to support global COVID-19 vaccination efforts.
This new milestone reflects commitments to governments across the world, including the United States, Australia, Brazil, Canada, France, Germany, India, Philippines, Saudi Arabia, South Africa, Spain and the United Kingdom, among many others. In total, BD is supporting pandemic orders for more than 40 countries, non-governmental organizations and other partners.
“Expanding vaccination efforts are bringing restored hope and a long-awaited return to normalcy in multiple countries around the world,” said Rick Byrd, president of medication delivery solutions for BD. “We are committed to continuing to support government partners and non-governmental organizations in these efforts to ensure health care providers on the front lines of this crisis have these much-needed injection devices to protect their patients from COVID-19.”
BD said it delivered more than 900 million injection devices around the world to date, with the remaining orders to be delivered between now and the end of 2022 to support vaccine administration.
BD continues to be in discussions with government agencies and non-governmental organizations on the need to plan ahead to ensure supply availability and place orders for delivery in late 2022 and into the future.
As part of its efforts, BD continues to closely plan supply capabilities to help ensure maximum volumes can be dedicated to COVID-19 efforts, while minimizing disruption for routine health care, annual flu vaccinations and childhood immunization programs.
BD also announced multiple capital investments to expand capacity for vaccination injection devices for COVID-19 and future pandemics. These include: Partnering with the U.S. government on a $70 million capital project to further expand BD’s operations and manufacturing capacity in Nebraska; adding new manufacturing lines for injection devices in the company’s Fraga, Spain manufacturing facility; and investing $1.2 billion over four years to expand and upgrade BD’s manufacturing capacity and technology for pre-fillable syringes and advanced drug delivery systems to allow for the continued growth of new injectable drugs and vaccines.